A couple of days ago, I posted this timeline of the SKB/GSK’s studies of Paxil in adolescents [paxil in adolescents: “five easy pieces”…]: I wanted to put some index of their profits from the drug during the period between publishing Paxil Study 329 and the time the patent expired. I failed at that. I couldn’t […]
Sometimes seeing something in another culture makes it stand out in bas-relief, easier to see with clarity. This news report in last year’s BMJ set off something of a firestorm. The group is the Ethical Standards in Health and Life Sciences Group [ESHLSG] with membership that included just about everybody. The article was an announcement […]
I try not to be boring and tedious, but sometimes it just can’t be helped. This post isn’t yet another commentary on Paxil Study 329, but it’s in the mix. It’s a timeline about all the studies SKB and GSK did on Paxil in adolescents. I think it’s of interest, but it may put others […]
No, this isn’t some old leftover image. I cut it from the program for the 60th Annual Meeting of the American Academy of Child and Adolescent Psychiatry coming up in a week or so. You might recall this more familiar version from 2005: Psychiatry as a Clinical Neuroscience Discipline by Thomas R. Insel, MD and […]
[SmithKlineFrench in former days] The corporate history of GlaxoSmithKline [GSK] starts with a Drug Store in Philadelphia [1830] and a Trading Company in New Zealand [1873], a history sketched through the many mergers on their website. But the parts that are of current interest were the acquisition of SmithKlineBeecham by GlaxoWelcome in 2000 and the […]
UPDATE 10:41 PM: [beginning at 1:37] “Well what we’ve done – well sequentially we’ve been increasing the level of data transparency around the data we generate on clinical trials. So we’ve been publishing clinical trials summaries for a while. We’ve now committed the publish all of our clinical trial reports that are detailed reports of […]
reckon this is real?
Several weeks ago in no country for old men…, I mentioned a study that found some new SNPs associated with Schizophrenia [Genome-wide association analysis identifies 13 new risk loci for schizophrenia] that estimated that 8,300 SNPs would be involved accounting for 32% of the liability for the disorder [how these numbers were derived is beyond […]
In the same old banners…, I was talking about two markers in psychiatry at the dawn of this new century that I didn’t understand. After psychiatry announced in 1980 that it was off and running to find some kind of biomedical legitimacy, there were twenty years of preoccupation with neurotransmitters and the medications that altered […]
I must’ve been pretty angry when I wrote that last post because my computer went belly-up in the process. Back in a while when the new one appears…